{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:39:16Z","timestamp":1774384756669,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. J. Drug Metab. Pharmacokinet."],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1007\/bf03190384","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T03:35:21Z","timestamp":1281065721000},"page":"109-121","source":"Crossref","is-referenced-by-count":31,"title":["Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects"],"prefix":"10.1007","volume":"26","author":[{"given":"J M A","family":"Sitsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F A","family":"Maris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"suppl 4","key":"BF03190384_CR1","first-page":"19","volume":"57","author":"T. Boer De","year":"1996","unstructured":"De Boer T. (1996): The psychopharmacological profile of mirtazapine. J. Clin. Psychiatry, 57 (suppl 4), 19\u201325.","journal-title":"J. Clin. Psychiatry"},{"key":"BF03190384_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00023210-199500041-00007","volume":"4","author":"J.M.A. Sitsen","year":"1995","unstructured":"Sitsen J.M.A., Zivkov M. (1995): Mirtazapine: clinical profile. CNS Drugs, 4, 39\u201348.","journal-title":"CNS Drugs"},{"key":"BF03190384_CR3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-199605050-00007","volume":"5","author":"R. Davis","year":"1996","unstructured":"Davis R., Wilde M.I. (1996): Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs, 5, 389\u2013402.","journal-title":"CNS Drugs"},{"key":"BF03190384_CR4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4088\/JCP.v59n0606","volume":"59","author":"D.P. Wheatley","year":"1998","unstructured":"Wheatley D.P., Van Moffaert M., Timmerman L., Kremer C. M. (1998): Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J. Clin. Psychiatry, 59, 306\u2013312.","journal-title":"J. Clin. Psychiatry"},{"key":"BF03190384_CR5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003495-199957040-00010","volume":"57","author":"K.J. Holm","year":"1999","unstructured":"Holm K.J., Markham A. (1999): Mirtazapine. A review of its use in major depression. Drugs, 57, 607\u2013631.","journal-title":"Drugs"},{"key":"BF03190384_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00044011-199713010-00005","volume":"13","author":"M.-L. Dahl","year":"1997","unstructured":"Dahl M.-L., Voortman G., Alm C., Elwin C.-E., Delbressine L., Vos R., Bogaards J.J.P., Bertilsson L. (1997): In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin. Drug Invest., 13,37\u201346.","journal-title":"Clin. Drug Invest."},{"key":"BF03190384_CR7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00004714-199110000-00007","volume":"11","author":"E. Leinonen","year":"1991","unstructured":"Leinonen E., Lillsunde P., Laukkanen V., Ykitalo P. (1991): Effects of carbamazepine on serum antidepressant concentration in psychiatric patients. J. Clin. Psychopharmacol., 11, 313\u2013318.","journal-title":"J. Clin. Psychopharmacol."},{"key":"BF03190384_CR8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"A. Bond","year":"1974","unstructured":"Bond A., Lader M. (1974): The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol., 47, 211\u20138.","journal-title":"Br. J. Med. Psychol."},{"key":"BF03190384_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0378-4347(98)00460-5","volume":"721","author":"F.A. Maris","year":"1999","unstructured":"Maris F.A., Dingler E., Niehues S. (1999): High performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma. J. Chromatography B, 721, 309\u2013316.","journal-title":"J. Chromatography B"},{"key":"BF03190384_CR10","volume-title":"TOPFIT Version 2.0 Pharmacokinetic and pharmacodynamic data analysis system for the PC","author":"G. Heinzel","year":"1993","unstructured":"Heinzel G., Woloszczak R., Thomann P. (1993): TOPFIT Version 2.0 Pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuutgart-Jena-New York: Gustav Fischer Verlag."},{"key":"BF03190384_CR11","first-page":"91","volume":"29","author":"K. Wesnes","year":"1989","unstructured":"Wesnes K., Simpson P., Christmas L., Anand R., McClelland G.R. (1989): The effects of moclobemide on cognition. J. Neural Transm., 29, 91\u2013102.","journal-title":"J. Neural Transm."},{"key":"BF03190384_CR12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF00191912","volume":"46","author":"R.L. Holland","year":"1994","unstructured":"Holland R.L., Wesnes K., Dietrich B. (1994): Single dose human pharmacology of umespirone. Eur. J. Clin. Pharmacol., 46, 461\u2013468.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF03190384_CR13","first-page":"323","volume":"29","author":"V.W. Steinijans","year":"1991","unstructured":"Steinijans V.W., Hartmann M., Huber R., Radtke H.W. (1991): Lack of pharmacokinetic interaction as an equivalence problem. Int. J. Pharmacol. Ther. Toxicol., 29, 323\u2013328.","journal-title":"Int. J. Pharmacol. Ther. Toxicol."},{"key":"BF03190384_CR14","first-page":"461","volume-title":"The pharmacological basis of therapeutics","author":"J.O. McNamara","year":"1996","unstructured":"McNamara J.O. (1996): Drugs effective in the therapy of the epilepsies. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman Gilman A., (eds). The pharmacological basis of therapeutics. New York: McGrawHill, Chapter 20, p. 461\u2013486."},{"key":"BF03190384_CR15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00007691-199904000-00005","volume":"21","author":"C.B. Eap","year":"1999","unstructured":"Eap C.B., Yasui N., Kaneko S., Baumann P., Powell K., Otani K. (1999): Effects of carbamazepine co-administration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther. Drug Monit., 21, 166\u2013170.","journal-title":"Ther. Drug Monit."},{"key":"BF03190384_CR16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s002280050527","volume":"54","author":"R.A. Lucas","year":"1998","unstructured":"Lucas R.A., Gilfillan D.J., Bergstrom R.F. (1998): A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur. J. Clin. Pharmacol., 54, 639\u2013643.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF03190384_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00044011-199815010-00006","volume":"15","author":"L.P.C. Delbressine","year":"1998","unstructured":"Delbressine L.P.C., Moonen M.E.G., Kaspersen F.M., Wagenaars G.N., Jacobs P.L., Timmer C.J., Paanakker J.E., Van Hal H.J.M., Voortman G. (1998): Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin. Drug Invest., 15, 45\u201355.","journal-title":"Clin. Drug Invest."},{"key":"BF03190384_CR18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/026988110001400207","volume":"14","author":"J.M.A. Sitsen","year":"2000","unstructured":"Sitsen J.M.A., Voortman G., Timmer C.J. (2000): Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J. Psychopharmacol., 14, 172\u2013176.","journal-title":"J. Psychopharmacol."},{"key":"BF03190384_CR19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00004714-200010000-00006","volume":"20","author":"F.S. Radhakishun","year":"2000","unstructured":"Radhakishun F.S., Van den Bos J, Van der Heijden BCJM, Roes KCB, O\u2019Hanlon J. (2000): Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J. Clin. Psychopharmacol., 20, 531\u2013537.","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03190384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03190384\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03190384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T23:59:36Z","timestamp":1558483176000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03190384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":19,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["BF03190384"],"URL":"https:\/\/doi.org\/10.1007\/bf03190384","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}